Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final ...
Ethical and statistical power issues limit the use of randomized controlled trials to study medication and vaccine use during ...
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT ...
Rosalind Franklin University announced today that Dr. Joanne Kwak-Kim, director of the university's Reproductive Medicine and ...
C5aR1 plays an important role in the immune cascade that causes tissue inflammation, particularly in neutrophil-mediated conditions. There’s an obvious overlap with Biogen’s own izastobart, an ...
T-bet expression is required for persistence of memory B cells that have rapid differentiation potential to become antibody-producing plasma cells in response to a second infection. The understanding ...
Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
About RAPT Therapeutics, Inc. RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with ...
Thought LeadersLiam O'Mahony, Barry Skillington & John MacSharryProf. of Immunology, Cheif Commerical Officer & Research PartnerAtlantia and Clinical Trials Though most people know that their immune ...
Immunology's transformative impact on global health, from Nobel Prizes to COVID-19 vaccines, underscores its critical role in ...
• Troy Randall – Med – Clinical Immunology and Rheumatology - The epigenetic modifier Kmt2a regulates humoral responses to influenza by orchestrating B cell function in the pre-inducible ...
Hosted on MSN
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development
WAYNE, PA & UTRECHT, Netherlands — NanoCell Therapeutics, Inc. announced the appointment of Prof. Zoltán Ivics, PhD, Jens Hasskarl, MD, PhD, and Jake Brenner, MD, PhD, to its Scientific Advisory Board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback